|
|
| Product Name: | E-7820 | | Synonyms: | E-7820;ER 68203-00;3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide;N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide;E 7820; E-7820;CS-2701;ER68203-00;E7820;E-7820;E 7820;289483-69-8;Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- | | CAS: | 289483-69-8 | | MF: | C17H12N4O2S | | MW: | 336.37 | | EINECS: | | | Product Categories: | | | Mol File: | 289483-69-8.mol |  |
| | E-7820 Chemical Properties |
| Boiling point | 626.2±65.0 °C(Predicted) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:67.0(Max Conc. mg/mL);199.19(Max Conc. mM) | | form | A crystalline solid | | pka | 8.17±0.30(Predicted) |
| | E-7820 Usage And Synthesis |
| Description | E7820 is a sulfonamide derivative and an angiogenesis inhibitor that inhibits bFGF- and VEGF-stimulated human umbilical vein endothelial cell (HUVEC) proliferation (IC50s = 0.1 and 0.081 μg/ml, respectively). It inhibits bFGF- and VEGF-stimulated tube formation of HUVECs in a concentration-dependent manner (IC50s = 0.2 and 0.24 μg/ml, respectively). E7820 selectively decreases the surface expression and mRNA levels of integrin α2 over CD31 and VE-cadherin in HUVECs. In vivo, E7820 (200 and 400 mg/kg) reduces tumor growth and inhibits angiogenesis in a WiDr colorectal cancer mouse xenograft model. It also reduces tumor weight in a panel of seven human colon, breast, pancreas, and kidney cancer mouse xenograft models, completely inhibits tumor growth in KP-1 pancreatic and LoVo colon cancer mouse xenograft models, and inhibits tumor growth in KP-1 and COLO 320DM mouse orthotopic transplantation models. | | storage | Store at -20°C |
| | E-7820 Preparation Products And Raw materials |
|